Cardiovascular Diabetology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800140, encodeId=538d80014058, content=很不错的杂志，编辑效率高，一审1个月，给了大修，6个审稿人（不知道为什么这么多审稿人😂）给了很多很好的意见，修回后一周左右accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200919/6a097961ca9c42c185295b14179a7194/45794bdef2854b5eac70a38f937a6355.jpg, createdBy=8e512207268, createdName=120c9b2em65(暂无昵称), createdTime=Sun Jun 28 17:06:38 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2510, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3915, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4086, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省)]

2022-01-16 123zz123

偏重的研究方向：临床队列
经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗

3974 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800140, encodeId=538d80014058, content=很不错的杂志，编辑效率高，一审1个月，给了大修，6个审稿人（不知道为什么这么多审稿人😂）给了很多很好的意见，修回后一周左右accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200919/6a097961ca9c42c185295b14179a7194/45794bdef2854b5eac70a38f937a6355.jpg, createdBy=8e512207268, createdName=120c9b2em65(暂无昵称), createdTime=Sun Jun 28 17:06:38 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2510, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3915, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4086, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省)]

2020-06-28 120c9b2em65(暂无昵称)

很不错的杂志，编辑效率高，一审1个月，给了大修，6个审稿人（不知道为什么这么多审稿人😂）给了很多很好的意见，修回后一周左右accept

233 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800140, encodeId=538d80014058, content=很不错的杂志，编辑效率高，一审1个月，给了大修，6个审稿人（不知道为什么这么多审稿人😂）给了很多很好的意见，修回后一周左右accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200919/6a097961ca9c42c185295b14179a7194/45794bdef2854b5eac70a38f937a6355.jpg, createdBy=8e512207268, createdName=120c9b2em65(暂无昵称), createdTime=Sun Jun 28 17:06:38 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2510, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3915, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4086, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省)]

2023-06-25 ms8000001858743317 来自北京

有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高

575 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800140, encodeId=538d80014058, content=很不错的杂志，编辑效率高，一审1个月，给了大修，6个审稿人（不知道为什么这么多审稿人😂）给了很多很好的意见，修回后一周左右accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200919/6a097961ca9c42c185295b14179a7194/45794bdef2854b5eac70a38f937a6355.jpg, createdBy=8e512207268, createdName=120c9b2em65(暂无昵称), createdTime=Sun Jun 28 17:06:38 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2510, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3915, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4086, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省)]

2023-03-28 123d2a9fm15暂无昵称来自湖南省

想请问已投过的大神们，peer review 的状态是送审了吗

621 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800140, encodeId=538d80014058, content=很不错的杂志，编辑效率高，一审1个月，给了大修，6个审稿人（不知道为什么这么多审稿人😂）给了很多很好的意见，修回后一周左右accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200919/6a097961ca9c42c185295b14179a7194/45794bdef2854b5eac70a38f937a6355.jpg, createdBy=8e512207268, createdName=120c9b2em65(暂无昵称), createdTime=Sun Jun 28 17:06:38 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2510, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3915, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4086, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省)]

2022-05-27 138*****882<手机用户>9442

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：糖尿病
经验分享：想问一下从接受到见刊再到sci收录大概要多长时间

2510 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800140, encodeId=538d80014058, content=很不错的杂志，编辑效率高，一审1个月，给了大修，6个审稿人（不知道为什么这么多审稿人😂）给了很多很好的意见，修回后一周左右accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200919/6a097961ca9c42c185295b14179a7194/45794bdef2854b5eac70a38f937a6355.jpg, createdBy=8e512207268, createdName=120c9b2em65(暂无昵称), createdTime=Sun Jun 28 17:06:38 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2510, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3915, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4086, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省)]

2023-03-16 ms5000001279026069 来自福建省

偏重的研究方向：心血管;主动脉夹层
经验分享：想问下大家，不是做糖尿病可以投吗

619 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800140, encodeId=538d80014058, content=很不错的杂志，编辑效率高，一审1个月，给了大修，6个审稿人（不知道为什么这么多审稿人😂）给了很多很好的意见，修回后一周左右accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200919/6a097961ca9c42c185295b14179a7194/45794bdef2854b5eac70a38f937a6355.jpg, createdBy=8e512207268, createdName=120c9b2em65(暂无昵称), createdTime=Sun Jun 28 17:06:38 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2510, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3915, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4086, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省)]

2023-10-10 ms8000000183026287 来自德国

10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。

474 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800140, encodeId=538d80014058, content=很不错的杂志，编辑效率高，一审1个月，给了大修，6个审稿人（不知道为什么这么多审稿人😂）给了很多很好的意见，修回后一周左右accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200919/6a097961ca9c42c185295b14179a7194/45794bdef2854b5eac70a38f937a6355.jpg, createdBy=8e512207268, createdName=120c9b2em65(暂无昵称), createdTime=Sun Jun 28 17:06:38 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2510, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3915, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4086, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省)]

2021-06-04 145dc5e9m77暂无昵称

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：心血管;糖尿病
经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。

3915 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800140, encodeId=538d80014058, content=很不错的杂志，编辑效率高，一审1个月，给了大修，6个审稿人（不知道为什么这么多审稿人😂）给了很多很好的意见，修回后一周左右accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200919/6a097961ca9c42c185295b14179a7194/45794bdef2854b5eac70a38f937a6355.jpg, createdBy=8e512207268, createdName=120c9b2em65(暂无昵称), createdTime=Sun Jun 28 17:06:38 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2510, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3915, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4086, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省)]

2020-07-20 jingziwei1988

偏重的研究方向：心血管;代谢综合征
经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么

4086 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1184997, encodeId=00c6118499ecf, content=偏重的研究方向：临床队列 经验分享：更换了新系统更好用了，就是想问下有状态是送审了15个审稿人，会有很多专家意见吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3974, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=abfe5461813, createdName=123zz123, createdTime=Sun Jan 16 23:10:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800140, encodeId=538d80014058, content=很不错的杂志，编辑效率高，一审1个月，给了大修，6个审稿人（不知道为什么这么多审稿人😂）给了很多很好的意见，修回后一周左右accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200919/6a097961ca9c42c185295b14179a7194/45794bdef2854b5eac70a38f937a6355.jpg, createdBy=8e512207268, createdName=120c9b2em65(暂无昵称), createdTime=Sun Jun 28 17:06:38 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2144587, encodeId=c7a0214458e9d, content=有幸中了一篇，从投稿到接受1月零2天，整体比较顺，杂志对统计要求较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=575, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=24e65466011, createdName=ms8000001858743317, createdTime=Sun Jun 25 09:03:13 CST 2023, time=2023-06-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2122350, encodeId=694b21223503e, content=想请问已投过的大神们，peer review 的状态是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=621, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70f32440168, createdName=123d2a9fm15暂无昵称, createdTime=Tue Mar 28 21:17:37 CST 2023, time=2023-03-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1222896, encodeId=fee3122289668, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病 经验分享：想问一下从接受到见刊再到sci收录大概要多长时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2510, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=967b2419476, createdName=138*****882<手机用户>9442, createdTime=Fri May 27 23:50:32 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119971, encodeId=19f421199e191, content=偏重的研究方向：心血管;主动脉夹层 经验分享：想问下大家，不是做糖尿病可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b548212056, createdName=ms5000001279026069, createdTime=Thu Mar 16 15:39:37 CST 2023, time=2023-03-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2161907, encodeId=e498216190e6d, content=10-5日投稿，目前还是Editor Appointed.请问最近的以色列战争对这个杂志有影响吗？因为这个杂志隶属于以色列大学。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=474, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b725453206, createdName=ms8000000183026287, createdTime=Tue Oct 10 09:54:28 CST 2023, time=2023-10-10, status=1, ipAttribution=德国), GetPortalCommentsPageByObjectIdResponse(id=970814, encodeId=23bd9e081415, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：心血管;糖尿病 经验分享：2月底投的，3月底一审，5月底修回，6月初通知accepted。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3915, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=998d5094007, createdName=145dc5e9m77暂无昵称, createdTime=Fri Jun 04 10:20:29 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803430, encodeId=91128034308d, content=偏重的研究方向：心血管;代谢综合征 经验分享：想请教一下，7月6日投稿，到现在状态还是New Submission?这样正常么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4086, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=649a2623893, createdName=jingziwei1988, createdTime=Mon Jul 20 08:25:54 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2191973, encodeId=568421919e3dc, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病心血管 经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=414, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606d8993093, createdName=ms1000000262909438, createdTime=Fri Mar 08 02:45:27 CST 2024, time=2024-03-08, status=1, ipAttribution=湖北省)]

2024-03-08 ms1000000262909438 来自湖北省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：糖尿病心血管
经验分享：已经修回了显示The editors' decision can take several weeks as they may consult peer reviewers.，看到说有再邀请审稿人的然后再重新修一遍

414 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务